219873-06-0Relevant articles and documents
Preparation method of 4-cyano-2-fluorobenzyl alcohol
-
, (2021/10/27)
The invention discloses a preparation method of 4-cyano-2-fluorobenzyl alcohol, and belongs to the technical field of medical intermediates. 3, 4-difluorobenzonitrile is adopted as a raw material and reacts with potassium bromide in the presence of a phase transfer catalyst, or 3-fluoro-4-bromobenzaldehyde and hydroxylamine are subjected to a dehydration reaction to obtain 3-fluoro-4-bromobenzonitrile, and then the 3-fluoro-4-bromobenzonitrile is subjected to Grignard reagent exchange and reacts with paraformaldehyde to obtain the 4-cyano-2-fluorobenzyl alcohol. The method is safe and stable, the obtained product is easy to purify, and the method has potential industrial amplification prospects.
3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
-
Page/Page column 138, (2018/04/11)
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
, (2016/08/29)
The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.